Restoring KLF9 function or targeting its regulatory networks (e.g., EZH2 inhibition) may offer novel therapeutic avenues to disrupt HCC progression and metastasis, warranting further exploration of its clinical potential. This evidence concerns the gene KLF9 and hepatocellular carcinoma.